Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours

Neuropathology and Applied Neurobiology

Volumn 30, Issue 5, 2004, Pages 456-471

  Neuwelt, Edward A ^a,b,c,d   Varallyay P ^a   Bago A G ^a   Muldoon, L L ^a,b   Nesbit, G ^a,b   Nixon, R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Blood brain barrier; Gene therapy; MR contrast agents

Indexed keywords

GADODIAMIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; ASTROCYTE; BRAIN TUMOR; CLINICAL ARTICLE; DRUG TUMOR LEVEL; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMAGE ENHANCEMENT; IMAGING SYSTEM; INTRAOPERATIVE PERIOD; MACROPHAGE; MALE; MALIGNANT NEOPLASTIC DISEASE; MICROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SIDE EFFECT; STAINING;

EID: 7044253728     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2004.00557.x     Document Type: Article

References (34)

1. Cairncross JG, Pexman JHW, De Rathbone MPI, Maestro RF. Postoperative contrast enhancement in patients with brain tumor. Ann Neurol 1985; 17: 570-2
2. Dickman CA, Rekate HL, Bird CR, Drayer BP, Medina M. Unenhanced and gadolinium-DPTA-enhanced MR imaging in postoperative evaluation in pediatric brain tumors. J Neurosurg 1989; 71: 49-53
3. Elster AD, DiPersio DA. Cranial postoperative site: assessment with contrast-enhanced MR imaging. Radiology 1990; 174: 93-8
4. Henegar MM, Moran CJ, Silbergeld DL. Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg 1996; 84: 174-9
5. Runge VM, Clanton JA, Price AC, Herzer WA, Allen JH, Partain CL, James AE. Evaluation of contrast-enhanced MR imaging in a brain-abscess model. Am J Neuroradiol 1985; 6: 139-47
6. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 1999; 9: 228-32
7. Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, Cohen JI, Petrillo A, Rink D, Neuwelt EA. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. Am J Neuroradiol 2002; 23: 510-9
8. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995; 13: 661-74
9. Shen T, Weissleder R, Papisov M, Bogdanov A, Brady TJ. Monocrystalline iron oxide nanocompounds (MION): physiochemical properties. Magn Reson Imaging 1993; 29: 599-604
10. Weissleder R, Bogdanov A, Neuwelt EA, Papisov M. Long-circulating iron oxides for MR imaging. Adv Drug Deliv Rev 1995; 16: 321-34
11. Egelhof T, Delbeck N, Hartmann M, Roth SU, Elste V, Heiland S, Sartor K. Can superparamagnetic contrast media improve MRI-tomographic images of experimental gliomas? Radiologe 1998; 38: 943-7
12. Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC, Enochs WS. MR imaging of phagocytosis in experimental gliomas. Radiology 1995; 197: 533-8
13. Zimmer C, Wright SC, Engelhardt RT, Johnson GA, Kramm C, Breakefleld XO, Weissleder R. Tumor cell endocytosis imaging facilitates delineation of the glioma-brain interface. Exp Neurol 1997; 143: 61-9
14. Kroll RA, Pagel MA, Muldoon LL, Neuwelt EA. Increasing volume of distribution to brain with interstitial infusion: dose, rather than convection, may be the most important factor. Neurosurgery 1996; 38: 746-54
15. Muldoon LL, Nilaver G, Kroll RA, Pagel MA, Breakefield XO, Chiocca EA, Davidson BL, Weissleder R, Neuwelt EA. Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus and iron oxide particles to normal rat brain. Am J Pathol 1995; 147: 1840-51
16. Muldoon LL, Pagel MA, Kroll RA, Roman-Goldstein S, Jones RS, Neuwelt EA. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery. Am J Neuroradiol 1999; 20: 217-22
17. Neuwelt EA, Weissleder R, Nilaver G, Kroll RA, Roman-Goldstein S, Szumowski J, Pagel MA, Jones RS, Remsen LG, McCormick C, Shannon EM, Muldoon LL. Delivery of virus-sized iron oxide particles to rodent CNS neurons. Neurosurgery 1994; 34: 777-84
18. Remsen LG, McCormick CI, Roman-Goldstein S, Nilaver G, Weissleder R, Bogdanov A, Hellström KE, Hellström I, Kroll RA, Neuwelt EA. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. Am J Neuroradiol 1996; 17: 411-8
19. Knauth M, Egelhof T, Roth SU, Wirtz CR, Sartor K. Monocrystalline iron oxide nanoparticles: possible solution to the problem of surgically induced intracranial contrast enhancement in intraoperative MR imaging. Am J Neuroradiol 2001; 22: 99-102
20. Di Chiro G, Brooks RA, Girton ME, Caporale T, Wright DC, Dwyer AJ, Horne MKr. Sequential MR studies of intracerebral hematomas in monkeys. Am J Neuroradiol 1986; 7: 193-9
21. Dina TS, Feaster SH, Laws ER, Davis DO. MR of the pituitary gland postsurgery: serial MR studies following transsphenoidal resection. Am J Neuroradiol 1993; 14: 763-9
22. Gomori JM, Grossman RI, Goldberg HI, Zimmerman RA, Bilaniuk LT. Intracranial hematomas: imaging by highfield MR. Radiology 1985; 157: 87-93
23. Gomori JM, Grossman RI, Hackney DB, Goldberg HI, Zimmerman RA, Bilaniuk LT. Variable appearance of sub-acute intracranial hematomas on high-field spin-echo. Am J Rad 1988; 150: 171-8
24. Spiller M, Tenner MS, Couldwell WT. Effect of absorbable topical hemostatic agents on the relaxation time of blood: an in vitro study with implication for postoperative magnetic resonance imaging. J Neurosurg 2001; 95: 687-93
25. Forsting M, Albert FK, Kunze S, Adams HP, Zenner D, Sartor K. Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. Am J Neuroradiol 1993; 14: 77-87
26. Spickler EM, Dion JE, Lufkin RB, Rachner T, Vinuela F, Duckwiler G, Bentson JR. The MR appearance of endovascular embolic agents in vitro with clinical correlation. Comput Med Imaging Graph 1990; 14: 415-23
27. Anzai Y, Lufkin R, DeSalles A, Hamilton DR, Farhani K, Black KL. Preliminary experience with MR-guided thermal ablation of brain tumors. Am J Neuroradiol 1995; 16: 39-48
28. Knauth M, Aras N, Wirts CR, Dörfler A, Engelhorn T, Sartor K. Surgically induced intracranial contrast enhancement: potential source of diagnostic error in intraoperative MR imaging. Am J Neuroradiol 1999; 20: 1547-53
29. Wirtz CR, Knauth M, Staubert A, Bonsanto MM, Sartor K, Kunze S, Tronnier VM. Clinical evaluation and follow-up results for intraoperative magnetic resonance imaging in neurosurgery. Neurosurgery 2000; 45: 1112-22
30. Penn RD, Walser R, Kurtz D, Ackerman L. Tumor volume, luxury perfusion, and regional blood volume changes in man visualized by subtraction computerized tomography. J Neurosurg 1976; 44: 449-57
31. Crocker EF, Zimmerman RA, Phelps ME, Kuhl DE. The effect of steroids on the extravascular distribution of radiographic contrast material and technetium pertechnetate in brain tumors as determined by computed tomography. Radiology 1976; 119: 471-4
32. Laster DW, Moody DM, Ball MR. Resolving intracerebral hematoma: alteration of the ring sign with steroids. Am J Rad 1978; 130: 935-9
33. Jeffries BF, Kishore RS, Singh KS, Ghatak NR, Krempa J. Contrast enhancement in the postoperative brain. Radiology 1981; 139: 409-13
34. Spetzger U, Thron A, Gilsbach JM. Immediate postoperative CT contrast enhancement following surgery of cerebral tumoral lesions. J Comput Assist Tomogr 1998; 22: 120-5